It appears that drug susceptibility in triple-negative BRCA1-proficient breast cancer cells is linked to the reduced expression of the BRCA1 protein in repairing DSBs after ruthenium exposure; meanwhile, olaparib targets the PARP enzyme, which leads to cancer cell death via synthetic lethality. Here, PARP1 is linked to breast carcinoma.